Hôpital Notre-Dame-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2022

  1. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334

2020

  1. Risk of secondary progressive multiple sclerosis: A longitudinal study

    Multiple Sclerosis Journal, Vol. 26, Núm. 1, pp. 79-90

2019

  1. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

    European Journal of Neurology, Vol. 26, Núm. 2, pp. 363-370

2018

  1. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

    Multiple Sclerosis Journal, Vol. 24, Núm. 5, pp. 642-652

2017

  1. Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

    Brain, Vol. 140, Núm. 9, pp. 2426-2443

  2. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

    The Lancet Neurology, Vol. 16, Núm. 4, pp. 271-281

2016

  1. Defining secondary progressive multiple sclerosis

    Brain, Vol. 139, Núm. 9, pp. 2395-2405

2015

  1. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

    Annals of Neurology, Vol. 77, Núm. 3, pp. 425-435